New Therapies for Ovarian Cancer.
New Therapies for Ovarian Cancer.
J Natl Compr Canc Netw. 2019 May 01;17(5.5):619-621
Authors: O'Malley DM
Abstract
After 3 to 4 decades of stagnation, several new options are available for the treatment of ovarian cancer, some of which produce longer survival compared with historical controls. Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence. Indications for bevacizumab have been extended, and there are now multiple combination chemotherapy regimens that include bevacizumab as part of initial treatment and as an option for maintenance therapy in select patients, both for first-line primary/adjuvant chemotherapy and for treatment of recurrent or refractory disease.
PMID: 31117037 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | History of Medicine | Ovarian Cancer | Ovaries